A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin

PHASE3CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

March 31, 2002

Primary Completion Date

August 31, 2002

Study Completion Date

August 31, 2002

Conditions
PainMultiple Sclerosis
Interventions
DRUG

GW-1000-02

Each actuation of GW-1000-02 (100 μl) delivered a dose containing 2.5 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD). The maximum permitted dose of study medication was eight actuations in any three hour period (20 mg THC/20 mg CBD) and 48 actuations in any 24 hour period (120 mg THC/120 mg CBD).

DRUG

Placebo

Each actuation of placebo (100 μl) delivered the excipients only. The maximum permitted dose of study medication was eight actuations in any three hour period and 48 actuations in any 24 hour period.

Trial Locations (1)

NR31 6LA

James Paget Hospital, Norfolk

Sponsors
All Listed Sponsors
lead

Jazz Pharmaceuticals

INDUSTRY